Summary Background Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two standard therapies across melanoma centers. Methods This prospectively-powered multicenter, retrospective cohort study was conducted in 15 melanoma centers in Australia, China, Germany, Italy, Japan, UK, and US. We included adult patients with resected stage III BRAF V600-mutant melanoma who received either adjuvant D/T or PD-1. The primary endpoint was recurrence-free survival (RFS). Secondary endpoints included overall survival (OS), recu...
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free surviv...
BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib ...
PurposeCombination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual B...
BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant ...
Background Previously, a study of ours showed that the combination of dabrafenib and trametinib impr...
Background Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib ...
BACKGROUND In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF or...
Simple Summary BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of ...
BackgroundPrevious analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival...
International audienceBackground: BRAF and MEK inhibitors combination, including dabrafenib (D) and ...
Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio...
In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-a...
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in p...
Background: In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF or B...
In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-a...
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free surviv...
BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib ...
PurposeCombination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual B...
BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant ...
Background Previously, a study of ours showed that the combination of dabrafenib and trametinib impr...
Background Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib ...
BACKGROUND In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF or...
Simple Summary BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of ...
BackgroundPrevious analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival...
International audienceBackground: BRAF and MEK inhibitors combination, including dabrafenib (D) and ...
Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio...
In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-a...
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in p...
Background: In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF or B...
In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-a...
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free surviv...
BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib ...
PurposeCombination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual B...